Cancer Center of South Florida Selects IntelliDose for All-Electronic Practice.

Clinical Oncology Software Facilitates Local Patient Access to Cutting-Edge Clinical Trials

WALTHAM, Mass. -- IntrinsiQ, LLC, the oncology practice experts, today announced that the Cancer Center of South Florida, PLLC has selected its flagship clinical software -- IntelliDose[R] -- to safely and efficiently manage critical chemotherapy treatments in its all-electronic practice.

The Cancer Center of South Florida, which opened its doors in July, will use IntelliDose to create best-practice treatment trees, eliminate the potential for human error in chemotherapy dosing, and streamline the efficiency of the practice.

The two-oncologist practice will also use IntelliDose to offer patients local access to cutting-edge clinical trials without needing to re-locate to the academic research centers that sponsor them. Only an oncology-specific clinical software solution can capture and track the highly regimented dosing -- and reporting -- involved in a clinical trial.

IntelliDose integrates seamlessly with the paperless practice's Centricity Electronic Medical Record (EMR) software, and provides the critical flexibility and functionality that the specialty of oncology requires.

"Cancer is a devastating disease - and oncology is a field of medicine where innovation is a constant. New treatment options become available every month, and patients deserve access to all possible options," said Dr. Abraham Schwarzberg of the Cancer Center of South Florida. "Whether a clinical trial is right for a patient or if they'll benefit more from the standard of care, IntelliDose allows us to give patients more choices than ever before."

The Cancer Center of South Florida joins the growing roster of oncology practices that have abandoned traditional paper-based process for electronically verified chemotherapy orders. Today, more than 500 oncologists at leading hospitals, health networks and private practices use IntelliDose to treat more than 19,500 patients each month.

"The practice of oncology is shifting under our feet. Physicians are seeing more patients, and patients have more options than ever to choose from," said Ted Owens, division general manager of IntrinsiQ's IntelliDose software division. "IntelliDose provides the safety checks and functionality needed to deliver the best possible patient care."

About IntrinsiQ

IntrinsiQ, LLC is the leading provider of medical oncology workflow solutions and the premier source of US oncology data and analysis. Each month, IntrinsiQ's market leading software application, IntelliDose([R]), captures the treatment decisions and details from more than 500 oncologists, for more than 19,500 unique patients, and regarding more than 7 million drug administrations. IntelliDose gives oncology physicians a clinical information system that ensures patient safety though automation and standards built specifically to meet the needs of a specific practice, saving staff time, maximizing reimbursement and reducing operating costs. For more information, please visit www.intrinsiq.com.